Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to premenopausal women with HR+/HER2- advanced breast cancer

Thursday, December 7, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

- Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and an early response with separation of the PFS curves as early as eight weeks[1]

Eric Althoff

Rosemarie Yancosek

Novartis Global Media Relations

Novartis Oncology Communications

+41 61 324 7999 (direct)

+1 862 778 9043 (direct)

+41 79 593 4202 (mobile)

+1 862 505 9021 (mobile)

[email protected]

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store